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Abstract
Background: A discrete choice experiment (DCE) is a method used to elicit participants’ preferences and the
relative importance of different attributes and levels within a decision-making process. DCEs have become popular
in healthcare; however, approaches to identify the attributes/levels influencing a decision of interest and to
selection methods for their inclusion in a DCE are under-reported. Our objectives were: to explore the development
process used to select/present attributes/levels from the identified range that may be influential; to describe a
systematic and rigorous development process for design of a DCE in the context of thrombolytic therapy for acute
stroke; and, to discuss the advantages of our five-stage approach to enhance current guidance for developing
DCEs.
Methods: A five-stage DCE development process was undertaken. Methods employed included literature review,
qualitative analysis of interview and ethnographic data, expert panel discussions, a quantitative structured
prioritisation (ranking) exercise and pilot testing of the DCE using a ‘think aloud’ approach.
Results: The five-stage process reported helped to reduce the list of 22 initial patient-related factors to a final set of
nine variable factors and six fixed factors for inclusion in a testable DCE using a vignette model of presentation.
Conclusions: In order for the data and conclusions generated by DCEs to be deemed valid, it is crucial that the
methods of design and development are documented and reported. This paper has detailed a rigorous and
systematic approach to DCE development which may be useful to researchers seeking to establish methods for
reducing and prioritising attributes for inclusion in future DCEs.
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Background
A discrete choice experiment (DCE) is a method used to
explore the relative importance of different attributes
within a decision-making process. Based on random util-
ity theory [1], DCEs operate on the tenet that there are
multiple attributes influencing decision-making and that
all decisions involve trade-offs between the range of ele-
ments that constitute the influential attributes. DCEs
offer a means through which the nuances of decision
making can be understood, by providing insights into
the often implicit trade-offs made, which are not easily
accessed through other research methods. DCEs have
been increasingly adopted to examine attributes influen-
cing decision-making in areas of healthcare, including
stroke rehabilitation [2, 3].
Traditionally, the broad study design of a DCE is
informed by literature review, expert opinion, theor-
etical arguments and/or qualitative work [4]. How-
ever, there is no standard development process for a
DCE for identifying a comprehensive list of attri-
butes that may influence the decision of interest and
the subsequent optimal selection of attributes for in-
clusion in the final design, necessary due to the fre-
quently large numbers and variable nature of type of
attributes that may be identified. Furthermore, there
is a lack of guidance on the optimal presentation of
choice sets or decision alternatives in DCEs. The
processes involved in the design of DCEs are often
poorly described, with little or no detail reported re-
garding the procedures for selection of attributes/
levels in the final design. In particular, there is a
dearth of guidance on procedures that can be under-
taken to select the most salient attributes and their
associated levels from the full range of attributes
that may influence the decision of interest and, when
reported, this information has been characterised as
“excessively brief” [4].
The International Society for Pharmacoeconomics and
Outcomes Research (ISPOR) has published two reports on
recommended best research practice in the development,
administration, analysis and reporting of DCEs [5, 6]. How-
ever, they do not offer a clear approach to certain important
aspects of DCE development; specifically how to select the
most salient attributes/levels for inclusion in choice scenar-
ios from the full range of attributes that may have an influ-
ence on the decision of interest; and administration in
terms of the optimal method of presenting choice scenarios
to respondents to maximise process/face validity of the
choice task.
With some notable exceptions [7, 8], there is a dearth of
examples of a clear, transparent DCE study design pro-
cesses in the published literature. Although researchers
have advocated the use of qualitative methods such as
one-on-one interviews, focus groups, analysis of policy
documents, and expert opinion to inform the design of
DCEs [4, 9], recent evidence suggests that the uptake and
reporting of qualitative methods to inform DCE design are
lacking. Vass et al. [10] found that of 254 healthcare DCEs
examined, 44% did not report using any qualitative
methods and only 11% reported relying on qualitative
methods extensively. This underuse, or lack of reporting of,
qualitative methods to inform DCE development inhibits a
clear understanding of whether a DCE design process has
been rigorous and systematic and thus inhibits the ability to
effectively evaluate the quality of the research. Quantitative
approaches, including ranking exercises and nominal group
techniques to support the process of selecting factors for
inclusion in DCEs have been outlined [7, 8] but to our
knowledge, there are no examples where both qualitative
and quantitative methods have been employed to inform
DCE design.
The validity of the results obtained from a DCE is
contingent on the quality of the study design process
[11]. When DCEs are conducted in circumstances
where there is little or no empirical evidence to
guide study design, documenting the design process
is especially important. Current reporting on DCE
design often does not provide sufficient information
to allow for an informed judgement to be made re-
garding the quality of a study [4, 9]. Increased trans-
parency at this stage of the process would offer
valued guidance to researchers, allowing them to
draw on approaches and methods that best suit the
objectives at hand. It would also support more ef-
fective critical appraisal of the findings of the re-
ported studies utilising DCEs. Robust methods
should underpin DCE design, yet it is often not pos-
sible to judge these processes, or whether there was
any structured development process involved, from
the limited information presented in many published
papers.
There have been calls for a minimum level of reporting
on the DCE development process, including the processes
used to collate an initial list of attributes, the analyses con-
ducted during this design stage (including sample details
and information on type of analysis conducted), processes
undertaken in reducing attributes to a manageable number,
and a brief description of the results of these processes [9,
10]. As each decision made during the DCE development
process can have implications for both the final design and
the validity of results obtained, the adherence of researchers
to these basic reporting conventions would improve the
transparency of DCE research and enable readers to better
judge the quality of such studies. By employing a DCE to
explore decision-making about thrombolysis in acute stroke
care as an exemplar, we describe a systematic, transparent
and iterative multi-method process to design an online
DCE.
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Decision context: Thrombolytic treatment in acute stroke
care
Intravenous thrombolysis using recombinant tissue
plasminogen activator is an effective medical treat-
ment for acute ischaemic stroke. Though there is
clear evidence of its efficacy and benefit in certain pa-
tient groups and it is promoted and supported by na-
tional guidelines [12–15], it remains underused, as
approximately one in five patients eligible for thromb-
olysis do not receive it [16]. Decision making about
whether or not to treat a stroke patient with thromb-
olysis is complex due to the time limited window for
treatment, potential difficulties in obtaining consent,
and the many clinical attributes that might influence
the balance between risk and benefit for individual
patients [17]. Early treatment of acute ischaemic
stroke with thrombolysis is associated with more
favourable outcomes, yet there is a small but signifi-
cant risk of adverse outcomes as result of treatment
[18]. Symptomatic intracranial haemorrhage occurs as
a complication in approximately 3–4% of patients,
which increases the probability of long-term disability
and death [16]. A DCE offers on optimal means of
better understanding the complexities of clinician
decision-making about intravenous thrombolysis in a
way that reflects decision making in practice.
The aim of this paper was to build on existing
DCE guidelines by describing a systematic and rigor-
ous process for DCE construction and choice set
presentation, using the exemplar case of clinical
decision-making for thrombolytic treatment during
acute stroke care.
Methods
Overview of DCE 5-stage design process
We designed hypothetical patient vignettes to mimic the
decision of interest as closely as possible, using a 5-stage
iterative process described by Fig. 1. This was process was
adopted because qualitative research was required to in-
form the design, but also in order to consider the nature
and relative importance of factors influencing choice (clin-
ical and non-clinical), and it was important to check the
material being constructed and validity of the choices with
clinicians. The decision of interest was in the form of a
binary response (decision to offer thrombolysis or not) as
this reflects routine clinical practice whereby clinicians are
faced with one patient at a time and must decide whether
or not to offer thrombolysis. Clinicians were likely to be
familiar and comfortable with vignettes as they are regu-
larly used in training and continuing professional
development.
Ethical approval was obtained from Newcastle Univer-
sity Research Ethics Committee (reference: 00720/2013).
Consent to participate was obtained for all those involved
in the study.
STAGE 1. Exploratory work
We considered all attributes that might be influential on
thrombolysis decision-making, as omitting important at-
tributes in the DCE may bias findings [2]. We drew on
previously gathered qualitative data collected for a previ-
ous research programme examining decision-making in
acute stroke [19] and on work to inform the develop-
ment of a computerised decision support tool for
thrombolysis in acute stroke care; COMPASS (COMPu-
terised decision Aid for Stroke thrombolysiS) [20]. This
included qualitative interview data on the views and ex-
periences of stroke clinicians about thrombolysis
decision-making, ethnographic data collected through
non-participant observation of thrombolysis decision-
making discussions, and data from the usability and
feasibility testing of COMPASS. Relevant literature was
also reviewed to identify further attributes that have been
documented to affect decision-making about thrombolysis
and attributes influencing medical decision-making more
broadly [21–26].
In addition, nine telephone-based semi-structured in-
terviews were conducted with stroke clinicians and ex-
perts in stroke research. Purposive sampling was used to
capture the views of experienced clinicians identified
through the literature review (who had not contributed
to the development of the COMPASS tool). We also tar-
geted clinicians from hospitals in both the upper and
lower quartiles of thrombolysis rates, based on figures
from national audits [27]. These interviews aimed to
identify any additional patient-related attributes or
levels that represented the borderline and/or difficult
cases; in particular the nature of trade-offs made be-
tween influential attributes and levels when making
thrombolysis decisions. Telephone interviews were
conducted due to the geographic spread of partici-
pants. Interviews were audio-recorded and transcribed
verbatim.
Anonymised transcripts were imported into QSR Inter-
national’s NVivo 9 to facilitate the coding and analysis of
data using a framework approach, where the initial frame-
work was guided by the interview guide (deductive ap-
proach) and additional codes were generated where
required (inductive approach) [28]. Codes were themed
where relevant and coding was discussed among the re-
search team to reach consensus. Analysis of interview data
and review of secondary data sources from the previous
research programme on stroke [19], alongside relevant lit-
erature, facilitated the generation of an initial long list of
potentially influential patient-related attributes on clinical
decision-making regarding thrombolysis.
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STAGE 2. Expert panel discussions – Procedure for
screening attributes and levels
Exploratory work commonly identifies too many attributes/
levels to include in DCEs and, due to sample size con-
straints and the potential for respondent cognitive burden,
it is often not practical or feasible to include all possible
combinations that may influence decision-making. By in-
cluding all potentially influential attributes and levels of
interest, the statistical power of a DCE to detect effects may
be reduced, due to the large number of possible combina-
tions of levels and the inability of a small sample size to ad-
equately assess all these various combinations. Methods are
needed to select the most important attributes and levels.
Although there are publications that provide generic advice
on DCE design [4, 9], there is a dearth of explicit guidance
on this process. A well-designed DCE has been described
as “one that has sufficiently rich set of attributes and choice
contexts, together with enough variation in the factor levels
necessary to produce meaningful behavioural responses.”
[29] Abiiro et al. [7] advise employing quantitative methods,
such as ranking exercises, to support the process of select-
ing attributes for inclusion to a manageable number. Prior
to the ranking exercise at the next phase, the expert multi-
disciplinary panel in the current study (consisting of three
stroke clinical researchers, one trainee stroke physician, two
patient representatives (from the UK Stroke Association),
two chartered psychologists, two health economists, and an
expert in shared decision-making) screened the long list of
attributes (generated during Stage 1) in terms of whether
they would be feasible or meaningful to include in a DCE,
which would then be further scrutinised using a structured
prioritisation/ranking exercise. Following this ranking exer-
cise and subsequent discussions, a set of inclusion and ex-
clusion criteria were agreed with reference to the study
objectives.
STAGE 3 - phase 1. Design of online structured
prioritisation exercise (SPE)
In order to identify the relative importance of various
patient-related attributes for clinical decision-making
and areas of uncertainty on specific attributes, an online
structured prioritisation exercise (SPE) was developed.
This was a ranking exercise performed by clinicians on a
single occasion to prioritise attributes related to clinical
decision-making for inclusion in the cases, to ensure
that the DCE was relevant without being excessively
long. It offered a means to elucidate a broader range of
views to inform the selection of the attributes and in
particular, questions were phrased to identify where un-
certainty and ‘cut-offs’ existed on individual attributes
regarding the suitability of the patient for thrombolysis.
This step was important for the current study as it was
widely recognised that individual clinicians had different
thresholds or cut-offs for decision-making. The findings
would inform expert panel discussions in the next phase
of the design process. Free text boxes were also provided
after each question. The SPE was hosted on Qualtrics
(www.qualtrics.com) and 30 stroke clinicians in the
north east of England were invited to participate. The
full SPE is available in Additional file 1.
Fig. 1 Summary of key stages of development process
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STAGE 3 - phase 2. Using the SPE to inform selection of
attributes/levels
The same expert panel assembled in Stage 2 then inde-
pendently ranked each attribute in order of priority for
inclusion in the DCE, indicated how they would oper-
ationalise them, and provided suggestions on possible
levels for each patient-related attribute. Results were
then aggregated and fed back to the panel to inform dis-
cussion on selection of the final list of attributes and
levels for inclusion. There was a need to compromise on
the perceived importance of attributes to ensure con-
cerns regarding sample size/design feasibility, ecological
validity (i.e., ensuring information presented is as con-
sistent as possible with information that would be avail-
able in a real life situation) and the potential impact of
unconscious attributes (e.g., patient ethnicity) were con-
sidered in the final attribute selection process. Issues
considered during these panel discussions were:
Ensuring clinical face validity
Realism of the patient information presented in vignettes
and that attributes/levels could plausibly occur together
was vital. Certain attribute levels could not reasonably
appear together meaningfully and therefore some initial
constraints were imposed on the design. For instance, a
modified Rankin score of 0 or 1 (indicating patient is
able to carry out all usual duties and activities) is im-
plausible for a patient described as having severe
dementia.
Ensuring sufficient information was present in vignettes
It was crucial that information on certain attributes was
provided in the vignettes (as either variable or fixed attri-
butes) in order for clinicians to reach a decision about the
offer of thrombolysis and for the decision-making process
to mimic real-life decisions as closely as possible. For in-
stance, stroke severity score and the results of the CT scan
were considered as vital information.
Anticipated sample size and resulting design considerations
Whilst more levels can define the true relationship be-
tween attributes and their influence on decision-making,
there is an inherent trade-off between this and the num-
ber of attributes and levels that can feasibly be included
in the DCE design [1]. Furthermore, there are important
considerations regarding the maximum numbers of attri-
butes and levels a participant can process simultan-
eously. Due to the limited size of the pool of potential
study participants in the current research, restricting the
number of variable attributes and levels per factor was
necessary to control the number of potential combina-
tions in order to ensure the DCE would have sufficient
statistical power to detect important effects. Based on
previous studies and estimates of the total number of
clinicians treating acute stroke patients in the United
Kingdom, a sample size of 150–200 was estimated as
achievable in the current study. This estimate represents
approximately 25–45% of the 422 clinicians registered as
‘Full Members’ of the British Association of Stroke Phy-
sicians [30]. Moreover, to address cognitive burden, we
judged that 12–16 hypothetical patient vignettes would
be the upper limit of decision vignettes that should be
administered to each participant (and this would be
tested/clarified in the piloting of the DCE in Stage 4).
Attributes that were considered important to provide
basic clinical information (but not included as variables
in the DCE) were included as fixed attributes in the de-
sign to remove subjectivity around interpretation of add-
itional issues. This provides common interpretation of
such attributes across respondents, whilst retaining face
validity. In the current study, blood glucose level was in-
cluded as a fixed attribute in each vignette (6.0 mmol/L).
An identical text description of a patient’s CT scan result
was included in all vignettes to remove subjectivity
around imaging interpretation. Definitions were also in-
cluded to standardise the interpretation of attributes and
levels. For instance, the standard definitions for modified
Rankin scores [31] used to assess pre-stroke dependency
were presented in each vignette. Definitions were also
provided for pre-stroke cognitive functioning and the
calculation for each level of stroke severity using the Na-
tional Institute of Health Stroke Scale (NIHSS) [32] to
ensure consistent interpretation.
Consideration of explicit versus implicit influences on
decision-making
There is strong evidence that implicit attributes can be in-
fluential in medical decision-making [23]. Therefore the ex-
pert panel also considered attributes that did not emerge
from the exploratory work and SPE. For instance, gender
may have a population-level effect on thrombolysis admin-
istration, with evidence of under-utilisation in women [33],
although this may reflect a different age and presentation
profile in women [34]. This is despite a pooled analysis of
randomised controlled trials demonstrating that women are
more likely than men to benefit from thrombolysis [35, 36].
Gender was not considered to be a conscious consideration
at the individual, bed-side level by the panel. Other attri-
butes that may have an implicit effect on decision-making
were ethnicity and social class. Panel discussions were fo-
cused on striking a balance between the inclusion of both
implicit and explicit attributes, which may influence
thrombolysis decision-making.
STAGE 4. Pilot testing
A pilot DCE was developed based on the decision made
by the expert panel. The generation of a fully balanced
design with all possible combinations of attributes and
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levels was not possible. Therefore, the software
programme, NGene (v1.1.1; http://www.choice-metrics.-
com/), was used to generate a fractional factorial (d-effi-
cient) design to generate a design that was as balanced
as possible, given the imposed constraints. A fractional
factorial design was employed due to the relatively large
number of variable attributes (nine) included in the final
DCE, with number of levels varying from two to six on
different attributes. This allowed for the testing of a sub-
set of possible combinations. Use of a blocked design
allowed the number of vignettes presented to any one
participant to be reduced to a number considered man-
ageable in pilot testing to avoid overburdening partici-
pants. In each block, 13 hypothetical patient vignettes
were presented to each participant.
The pilot testing of the initial DCE employed a ‘think
aloud’ approach that was guided by best practice guide-
lines [37]. This method asks participants to verbalise
what they are thinking when responding to the survey,
which can help to reveal vague or confusing questions,
or other issues in need of clarification. The aim of this
pilot stage was to facilitate further testing of the credibil-
ity of the vignettes among the population of interest,
examine participants’ understanding and interpretation
of the task and questions, check the usability of the sur-
vey on different systems and browsers, and gauge how
long the survey might take to complete. Changes were
made to the design and wording of vignettes and phras-
ing of questions during the piloting process to ensure
any amendments could be tested. Furthermore,
post-pilot testing was undertaken by the expert panel
prior to the formal data collection phase. The pilot test-
ing protocol is available in Additional file 2.
STAGE 5. Final expert panel discussions
At this stage, the same expert panel from Stage 2 were
engaged to finalise the DCE. Refinements were made to
the online survey based on outcomes of pilot testing and
final amendments to questions and the instructions to
the DCE were agreed.
Results
Given the underreporting/lack of development work in
DCE design in the field, we have developed a 5-stage
process which offers a replicable and transparent strat-
egy, with methods to identify a comprehensive list of at-
tributes that may potentially influence a decision of
interest. Underreporting of the design process highlights
that procedures used to select the most salient attributes
for inclusion in the final design need to be based on ex-
plicit criteria to permit a judgement about bias and ex-
ternal validity of the findings to be made. Furthermore,
presentation of choice sets in DCEs using traditional
methods may lack sensitivity to decision-making
contexts, which indicated a need to identify the optimal
mode of presenting choice sets to respondents to maxi-
mise face/clinical validity of the choice task that is im-
portant for augmenting external validity of findings from
DCEs.
Stage 1. Full list of attributes identified from initial
exploratory work
Table 1 displays all the patient-related attributes identified
as potentially important in thrombolysis decision-making
based on: (i) the analysis of new and existing qualitative
data sets on the views and experiences of stroke clinicians
involved in thrombolysis decision-making; and (ii) a re-
view of relevant literature.
Stage 2. Expert panel discussions
The expert panel reviewed the list generated by Stage
1 and concluded it was comprehensive and relevant.
There was a need at this stage to begin the process
of reducing the list to the most important attributes.
A set of criteria were agreed to focus the scope of
the study:
Table 1 Patient-related attributes that could influence decision-
making about thrombolysis
1. Systolic blood pressure
2. Diastolic blood pressure
3. Blood glucose level
4. Patient frailty
5. Stroke severity (NIHSS score)
6. History of hypertension
7. History of stroke
8. Anticoagulation status / INR level
9. Aspirin monotherapy
10. A patient’s level of social support
11 Major surgery in past 3 months
12. Presence of diabetes at time of presentation
13. Patient age
14. Patient ethnicity
15. Patient gender
16. Socioeconomic status of patient
17. Stroke onset time to treatment
18. Recent infarction on CT/MRI scan
19. Pre-stroke cognitive functioning / capacity / comprehension of risk
information
20. Pre-stroke dependency status
21. Patient/relative values, knowledge and views on thrombolysis
22. Co-morbidities
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Removal of attributes that could be considered as related
to uncertainty regarding the diagnosis of acute ischaemic
stroke
This was considered prudent based on the rationale
that: (i) incorporating diagnostic uncertainty has
methodological implications for the design of the pa-
tient vignettes and interpretation of results from the
DCE. Given that a diagnosis of acute ischaemic stroke
represents a gradient of certainty (and includes con-
sideration of differential diagnoses such as transient
ischaemic attack and stroke mimics) this does not
lend itself well to the DCE framework. Furthermore,
diagnostic uncertainty was beyond the scope of the
aims stated in the study protocol [38] to explore at-
tributes influencing decisions to offer thrombolysis, as
opposed to what attributes influence diagnosis.
Removal of redundant/uninformative questions from the
SPE
Questions were excluded if the panel agreed that the
area of uncertainty on any attribute had been clearly
identified by the literature and/or qualitative data. For
instance, a question regarding patient’s pre-stroke status
using the modified Rankin Scale (mRS) was removed as
the panel were confident that most clinical variation in
decision-making exists between mRS 2 and 3.
Furthermore, attributes were omitted that have been
shown to have a population level effect in research stud-
ies but were not considered by the expert panel (or were
not identified in exploratory interviews) to be important
for decision-making about thrombolysis at the individual
patient level (e.g., current use of aspirin).
Stage 3 (phase 1). Results of on-line survey (SPE)
The online SPE was live for six weeks and 11 clinicians
completed the survey (37% response rate). Results are sum-
marised in Additional file 3.
Stage 3 (phase 2). Results of second round of expert
panel discussions
The ISPOR report on good research practices advises
that discussion with experts is an approach that can be
employed to help reduce the list of attributes [6]. The
expert panel completed a ranking exercise to generate
discussion and to help work towards a consensus regard-
ing the importance of attributes for inclusion, and which
attribute levels should be varied and which should be
fixed. The results of this exercise are presented in
Table 2. In consideration of the potential influence of
implicit attributes on decision-making about thromboly-
sis, the panel elected to include ethnicity and gender as
variable attributes in the DCE. Socio-economic status
was also considered for inclusion in the DCE. However,
due to the challenging nature of representing this
information in vignettes and the potential influence of
type of employment (e.g. manual work) in judgements of
risk/benefit, it was decided to omit this attribute. Based
on these discussions, it was agreed to include seven fixed
attributes and nine variable attributes (see Table 3).
The expert panel also considered the attribute levels
for inclusion and discussions were informed and guided
by the results of the exploratory work and by the SPE,
which specially explored the ‘grey’ areas of decision mak-
ing, or attributes where respondents felt there was inad-
equate evidence to inform decision-making (e.g.,
cognitive impairment). Based on the staged process, the
expert panel reviewed results and selected attribute
levels to explore these ‘grey’ areas of decision-making.
Stage 4. Results of pilot testing
Sixteen clinicians were invited to take part in pilot test-
ing. Six agreed to take part and fully completed the pilot.
The ‘think aloud’ approach helped to refine language
used in the survey, ensured questions were interpreted
by participants as intended, and confirmed sufficient in-
formation was presented in the vignettes to allow clini-
cians to reach a decision. The testing revealed that
vignettes were credible, although a number of implaus-
ible combinations were identified and added as con-
straints to the design. These included low NIHSS scores
with aphasia combined with moderate/severe dementia.
These combinations were therefore excluded from the
design.
Unexpected issues also emerged. For example, when two
clinicians read that symptom onset began 4 h and 15 min
ago, they factored in time to prepare the thrombolysis bolus
into their decision-making (as the thrombolysis time win-
dow for treatment is up to 4.5 h post symptom onset).
Therefore, thrombolysis bolus preparation time was in-
cluded as an additional fixed attribute, stating that the treat-
ment dose could be prepared within 5 min to eliminate this
as an influence on clinicians’ decision-making (Table 3).
Stage 5. Final attributes and levels for inclusion in DCE
Final amendments were made by the expert panel based
on feedback received during the pilot stage. As pilot par-
ticipants felt that the patient vignettes contained suffi-
cient information to allow them to reach an informed
decision about the offer of thrombolysis, the nine attri-
butes (and associated levels) used in the pilot were
retained for inclusion in the final DCE (Table 4). Defini-
tions for variable attribute levels in the vignettes were
also finalised by the expert panel based on the feedback
from pilot participants (see Additional file 4).
Key considerations and final design of DCE
Key considerations of the development of this online DCE
included the size of the population of interest, the number
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of combinations of attribute levels, respondent burden
and likely response rate. It was crucial for the expert panel
to consider these issues alongside the perceived import-
ance of various attributes and levels. Based on this
five-stage design process, we were confident that we had
provided sufficient information to allow clinicians to reach
a decision by using both fixed and variable attributes. A
sample vignette is displayed in Fig. 2 to demonstrate how
the hypothetical patient attributes and levels were pre-
sented to clinicians.
Discussion
The aim of this paper was to build on existing DCE de-
sign guidelines by describing a systematic and rigorous
development process using an exemplar case describing
the development of a clinically-valid DCE to investigate
Table 2 Stage 3 (Phase 2) Expert panel ranking exercise results
(n = 6)
Attribute Mean
rank (SD)a
Median Suggested levels
Systolic BP 1.67 (1.2) 1 • 140 mm/Hg
• 175 mm/Hg
• 180 mm/Hg
• 185 mm/Hg
• 200 mm/Hg
Pre-stroke
dependency status
4 (2.6) 4 • mRS 1
• mRS 2
• mRS 3
• mRS 4
Pre-stroke cognitive
status
5.33 (2.6) 5.5 • No impairment
• Mild impairment
• Moderate impairment
• Severe impairment
Stroke Severity
(NIHSS)
6.5 (2.9) 7 • NIHSS 2
• NIHSS 3
• NIHSS 5
• NIHSS 23
• NIHSS 25/26/27
SBP (after reducing) 6.6 (4.7) 5 • 185 mm/Hg
• 190 mm/Hg
• 200 mm/Hg
INR/Anticoagulation 6.7 (2.7) 5.5 • < 1.6
• < 1.7
• < 1.8
• 2
Diastolic BP 6.8 (5.2) 6 • 100 mm/Hg
• 110 mm/Hg
Table 2 Stage 3 (Phase 2) Expert panel ranking exercise results
(n = 6) (Continued)
Attribute Mean
rank (SD)a
Median Suggested levels
• 115 mm/Hg
• 120 mm/Hg
Frailty 6.8 (3.9) 7 • Composite measure using
comorbidities,
description of needs
(i.e., walking stick)
• “patient you [do not]
perceive as frail”
Time since symptom
onset
7.8 (6.1) 7 • < 1 h
• < 3 h
• 4 h
• 4 h 15/20 mins
Recent major
surgery
8.3 (3.6) 7.5 • Percutaneous coronary
intervention
• Hip replacement
• Laparotomy
Previous stroke 9.2 (4.3) 10.5 • Combine with stroke
severity?
• 2 weeks ago
• 4 weeks ago
• 3 months ago
Comorbidities 9.8 (2.6) 10 • Disability-related
• Chronic disease
• Illness presenting
bleeding risk
Blood glucose level
(mmol/L)
10.8 (3.1) 11 • 16/19
• 22
• 25
• 27
Patient/relative
preferences
11.4 (2.6) 12 • No family present
• Family present and eager
for patient to be treated
• Family present and worried
about bleeding risk
Willingness to treat
blood glucose
11.6 (3.7) 11 • Option to treat before
thrombolysis decision
• Option to present already
treated level
Patient age 12.7 (5.7) 14.5 • 62/68/75
• 80 / 8585
• 95
Social support 15 (3.1) 16 • Indicator of dependency?
• Use as part of frailty
composite measure?
Presence of diabetes 15.4 (2.4) 16 • No history of diabetes
• Patient has diabetes
a Note: Lower mean rank indicates higher perceived importance
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clinical decision-making about thrombolytic treatment
in acute stroke care.
Previous literature has often pointed to the underre-
porting of aspects of DCE design. The under-reporting
(or lack of DCE development work) on crucial aspects of
this design process makes a strong case for adding add-
itional details to the minimum reporting guidelines in
order for readers to judge quality and to lend confidence
in DCE results. Despite existing guidance on DCE de-
sign, development and evaluation [2, 4] and calls to im-
prove reporting on this process [4], underreporting is
still prevalent [10]. However, as noted by others [11],
this may be due to tensions between journal editors and
authors regarding space constraints and word limits.
Nonetheless, journals are increasingly offering authors
the opportunity to include supplementary material as
online appendices and we urge authors to avail
themselves of this, where possible, to ensure adequate
and comprehensive reporting on DCE research.
The value and strength of the results obtained from
a DCE are contingent on the quality of the study de-
sign process. When DCEs are conducted in circum-
stances where there is little or no empirical evidence
to guide study design, documenting the design
process is especially important. Increased transparency
at this stage would offer guidance to researchers,
allowing them to draw on approaches and methods
that best suit the objectives at hand, or to develop,
extend or replicate existing DCEs. Robust methods
should underlie DCE design, yet it is often not pos-
sible to judge these processes, or whether there was
in fact any development process involved, from the
limited information presented in many published
papers.
Table 3 Fixed attributes used in DCE and rationale for inclusion
Attribute Rationale for inclusion Fixed level Rationale for level
Blood glucose level Variable levels may result in diagnostic
uncertainty
6 mmol/L Average blood glucose level based
on SITS data of treated patients
CT scan text description To avoid skill/subjectivity around
interpretation of scans
CT scan was conducted and is
consistent with ischaemic stroke;
it shows no haemorrhage or
new ischaemic changes
Decided not to include image due
to potential variability in CT image
interpretation skill and subjectivity;
difficulty finding scans to match
multitude of various patient
characteristics. Text description
deemed most appropriate to
remove diagnostic uncertainty
To ensure confirmation of diagnosis
of acute ischaemic stroke
Anticoagulation status While it was deemed an influential
attribute, only minority of stroke patients
take an anticoagulant and therefore it
was not included as variable attribute
patient is not on anticoagulation
therapy
To avoid any issues surrounding
INR levels that could complicate
the decision to offer thrombolysis
Bleeding risk / recent surgery Only relevant for a minority of patients.
Challenging to operationalise variable
and comparable levels in vignettes
no recent history of major
bleeding
Diabetes Not ranked as important in vignettes no history of diabetes
Included as fixed attribute for clinical
validity
Patient consent/ family
assent
assume either patient consent of
family assent is available for
treatment
Other / Comorbidities there are no other attributes which
would deter treatment
Due to difficulty defining fully and
generating comparable and feasible
levels of comorbidities. Potential
overlap with pre-stroke cognitive
and pre-stroke dependency status
Fixed attributes included post-pilot
testing (Stage 4)
Handedness of patient “All patients are right-handed” To clarify and ensure the deficits
will be interpreted consistently
across all level of stroke severity
(NIHSS)
Licenced dose bolus
preparation time
“can be prepared for administration
within 5 min”
Pilot testing revealed that
participants would attribute in
variable times in their decision-
making so stating this will help
control this potential error
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Previous work by Coast et al. [4] indicates that
underreporting of processes to design DCEs is a
problem in the wider DCE published literature. As
each decision made during the DCE development
process can have implications for the final design and
the results obtained, we strongly urge that, at a mini-
mum, researchers should be required to report details
of the development processes of the DCE design in-
cluding the rationale for the approach adopted, details
of analyses conducted, processes to narrow down at-
tributes/levels, results of analyses, and details of the
sample. Furthermore, piloting of the DCE is a crucial
step and researchers should document what the aim
of piloting was, the results of piloting, and provide
details on the sample used and any changes made
post-piloting. Finally, the content and face validity of
the DCE must be considered and maximised during
the design process in order for the study and its
results to be considered meaningful. The adherence
of researchers to these basic reporting conventions
would improve the transparency of DCE research.
To exemplify this, we have established and described
an iterative process that is transparent, rigorous and sys-
tematic, providing rationales for decisions made at each
stage of the DCE design. This five-stage development
process was used to design an online DCE utilising
choice sets in the form of patient vignettes to examine
attributes that influence the clinical decision to offer
thrombolysis to acute ischaemic stroke patients. A re-
view of relevant literature and secondary analysis of
qualitative data in Stage 1 enabled the compilation of a
comprehensive list of attributes that might influence
clinical decision-making about thrombolysis. Through
expert panel discussions, and applying explicit inclusion/
exclusion criteria, Stage 2 enabled selection of attri-
butes/levels that could be meaningfully included in the
Table 4 Final list of variable attributes and levels in the DCE
Attribute Levels Rationale
1. Systolic blood pressure a. 140 mm/Hga
b. 185 mm/Hg
c. 200 mm/Hg
• Highest ranked attribute in Stage 3 phases 1 and 2
• Levels include those across rage from ‘safe to offer
thrombolysis’ to ‘grey are’ to ‘outside the
thrombolysis licencing guidelines’
2. Gender a. Malea
b. Female
• To increase clinical face validity
• To examine if gender has an unconscious influence
on decision-making
3. Age a. 68a
b. 85
c. 95
• Included for purposes of ecological and face validity
• Evidence from exploratory work that some clinicians
may take patient age into account and adhere to
current licensing guidelines
4. Frailty a. you do not perceive as fraila
b. you perceive as frail
• Very challenging to adequately define frailty due to
subjectivity in how clinicians view/consider it
• Aim was to trigger perception of frailty in patient
and therefore the current phrasing was considered
optimal to meet aim
5. Time since symptom onset a. 50 mina
b. 2 h 30 mins
c. 4 h 15 mins
• Potential greater benefit of very early treatment
time (50 mins) included to compare to mid-point
in time window and
rapidly approaching end of window (4 h 15mins)
6. Pre-stroke dependency (mRS) a. mRS 1
b. mRS 3
c. mRS 4a
• Qualitative work suggested mRS 3 was the grey
area in dependency
7. Pre-stroke cognitive functioning a. No history of memory problemsa
b. Moderate dementia
c. Severe dementia
• Exploratory work suggested dementia/cognitive
functioning could influence decision to offer
thrombolysis
8. Ethnicity a. whitea
b. Afro-Caribbean
c. Asian
• Included as an attribute that may have an implicit
effect on decision-making
• Included as this is information that would be
obvious in a typical decision
9. NIHSS (stroke severity) a. NIHSS 2 (without aphasia)a
b. NIHSS 2 (with aphasia)
c. NIHSS 5 (without aphasia)
d. NIHSS 5 (with aphasia)
e. NIHSS 14a
f. NIHSS 23
• Presence or absence of aphasia deemed
very important in previous stage and therefore
was included at lower NIHSS scores (mild strokes)
to assess whether it would influence decision-
making.
• NIHSS 14 included as it is the SITS mean
score (for treated patients)
• NIHSS 23 considered a severe stroke
areference category
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choice sets of this DCE. Discussions in Stage 2 informed
the design of a structured prioritisation exercise (SPE) in
Stage 3 that consisted of a ranking exercise to prioritise
attributes and levels for inclusion in the patient vi-
gnettes. Findings of ranking exercises guided subsequent
expert panel discussions to reach consensus on the DCE
choice sets and on-line survey design. This was followed
by a pilot phase incorporating a think aloud approach
(Stage 4), and in turn finalising the design of the DCE
choice sets using fractional factorial methods (Stage 5).
This paper contributes to the literature on DCE devel-
opment by clearly documenting a systematic and rigor-
ous, iterative process to derive the final number and
type of attributes, attribute levels and associated oper-
ational definitions for inclusion in an online DCE. It
builds on ISPOR guidelines [5, 6] by providing explicit
guidance on a five-stage process, which may be particu-
larly beneficial when there is little or no previous re-
search to guide DCE design. This transparency in the
development process of a DCE (process validity) to
understand the decision of interest (decision to offer
thrombolysis or not), as well as information used by cli-
nicians in their decision-making, confers confidence in
the rigour and reliability of findings and applicability to
the real-world (ecological validity) [39]. Although we
have outlined a linear approach to achieve this, this de-
velopment process is flexible and may adapted as
appropriate.
This development work highlights the crucial import-
ance of an iterative design process for augmenting the
clinical face validity of the choice task in terms of (i)
mode of administration (paper-based or electronic); (ii)
identification and optimal selection of variable and fixed
attributes and associated levels to include in choice sets;
(iii) form of choice set presentation (textual versus trad-
itional tabular approach, and order of information pres-
entation;) and (iv) the necessity of piloting to augment
clinical face validity, and in turn external validity, and
test acceptability of choice sets by the target population,
prior to the data collection phase.
Identification and optimal selection of variable and fixed
attributes, and associated levels, to include in choice sets
is critical. Given the limited size of the population of inter-
est in the current DCE, the size of the research sample
(based on explicit inclusion criteria) and likely response
rate were important considerations to establish the feas-
ible DCE design options that were likely to be achievable
and testable within an acceptable level of statistical power.
Additional issues to consider alongside selection processes
are (i) whether levels of attributes cohere together
Fig. 2 Sample patient vignette
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meaningfully within choice sets to identify any potential
design constraints, (ii) whether the information within
choice sets provide sufficient information to clinicians to
make a decision (i.e., are specific levels of fixed attributes
warranted for the purposes of clinical face validity), and
(iii) if the levels of variable attributes elicit variability in
the respondents in terms of the clinical decision-making
about thrombolysis.
The presentation of attributes and levels in the form
of hypothetical patient vignettes in accordance with
preferences of clinicians differs from the traditional form
of presentation of DCE choice sets and constituted a
novel aspect of the study. The intended respondents are
familiar with this form of information presentation dur-
ing clinical training; this was therefore the optimal
method of information presentation to enhance clinical
and external validity. Furthermore, attribute order/place-
ment in the vignette was decided based upon the infor-
mation that would be available to the clinician
immediately and the typical order in which additional
information may be obtained. The order of presentation
of attributes was also informed by work to develop the
COMPASS decision support tool [20].
Whilst this DCE was designed for the specific purpose of
elucidating attributes influencing the decision to offer
thrombolytic therapy for patients with acute stroke, we
contend that a key strength of this study is the development
of a five-step approach that can be transferable to other re-
search contexts. We believe the steps undertaken can assist
researchers in determining the attributes of interest and en-
suring broad input into the DCE design process. The num-
ber of interviews to conduct with expert informants or the
number of participants required to adequately inform an at-
tribute prioritisation exercise will likely differ considering
the study subject and the availability of previous relevant
research.
It is often difficult to predict or know in advance the
number of development stages required for any particu-
lar study [9]. We propose that this design framework of-
fers structure to researchers to apply to inform design
decisions. The exploratory phase and involvement of
subject experts beyond the research team is crucial to
avoid narrowing the scope too early. After this stage, a
structured exercise to agree priorities can be useful to
understand those attributes that are strong influences or
demonstrate high variability on a decision of interest. De-
pending of the aims of the research, one or both of these
issues may prove more important to consider in DCE de-
sign. The use of the ‘think aloud’ approach is a very useful
technique for pilot testing prior to data collection. It can
alert researchers to ambiguous questions or terms, explore
usability of the instrument and can highlight if partic-
ipants feel the choice set is missing important infor-
mation required to make a clear decision. The expert
panel, comprising individuals with various perspec-
tives and expertise on the decision of interest, was a
useful resource during the research and we would ad-
vocate the use of such a panel to support
decision-making in DCE design. It also enabled con-
sideration of attributes that could potentially exert an
unconscious influence on decision-making (as sug-
gested by the evidence base) that may not have
emerged during the qualitative research.
Among the challenges inherent in our approach is
the valuation of data and how best to use the mul-
tiple data sources that were generated during the de-
velopment process. Stages 1–4 shaped the study in
terms of mode of administration and facilitated selec-
tion of variables identified as likely to be contributing
most to variation in the decision of interest. Practical
issues such as adherence to good practice guidance
on design of survey questionnaires to maximise inter-
pretability and response rates [40, 41] are also key
considerations, including establishing predicted sam-
ple size informed by robust estimates of population
size and response rates to similar studies. Sample size
estimates are typically determined by the number of
attributes and levels and what constitutes a meaning-
ful effect size in the context of the study. These as-
pects are often not known a priori and therefore it
can be challenging to incorporate this in the design
planning process. We believe the steps described in
this paper can be adopted and adapted to suit many
other areas of research to inform appropriate DCE
design. We encourage others to replicate the ap-
proach adopted here to explore the appropriateness
of the design method to other domains.
Conclusions
The sub-optimal reporting on crucial aspects of DCE de-
sign makes a strong case for minimum reporting guide-
lines. The onus is on both researchers and journal editors
to ensure a minimum reporting standard is adhered to in
order to indicate quality and bestow confidence in DCE
results. Our five-stage design process has demonstrated
that adopting a rigorous staged approach to the develop-
ment of DCEs yields enhanced face validity of the choice
task and strengthens the external validity of findings. The
iterative, transparent development process described here
could be applied to other settings and index decisions and
would be a valuable adjunct to existing guidance on devel-
opment of DCEs.
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